Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

61. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial.

Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. 12642046 2003 03 18 2003 04 04 2015 06 16 0140-6736 361 9360 2003 Mar 08 Lancet (London, England) Lancet Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial (...) : a randomised controlled trial. 809-13 There is serological and epidemiological evidence of an association between Chlamydia pneumoniae infection and coronary artery disease. Results of previous smaller studies have indicated a reduction of recurrent ischaemic events in patients with acute coronary syndrome when given macrolide antibiotics. We aimed to assess whether short-term treatment with the macrolide antibiotic azithromycin reduces recurrent ischaemic events in patients admitted for unstable angina

Lancet2003

62. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. 13129985 2003 09 17 2003 09 25 2016 10 17 1538-3598 290 11 2003 Sep 17 JAMA JAMA Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. 1459-66 Several lines of evidence have implied an association between Chlamydia pneumoniae infection and atherogenesis. To determine the effect of 12 weeks (...) azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2-12; n = 3879) or placebo (n = 3868). The primary event was the first occurrence of death from any cause, nonfatal reinfarction, coronary revascularization, or hospitalization for angina. Patients were followed up until 1038 events accrued. After a median of 14 months of follow-up, there was no significant risk reduction in the likelihood of a primary event with azithromycin vs placebo (7% [95% confidence interval, -5% to 17%], P

JAMA2003

63. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. 14519709 2003 10 01 2003 10 07 2016 10 17 1538-3598 290 13 2003 Oct 01 JAMA JAMA Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. 1749-56 Treatment strategies for cystic fibrosis (CF) lung disease include antibiotics, mucolytics, and anti-inflammatory therapies. Increasing evidence suggests (...) that macrolide antibiotics might be beneficial in patients with CF. To determine if an association between azithromycin use and pulmonary function exists in patients with CF. A multicenter, randomized, double-blind, placebo-controlled trial conducted from December 15, 2000, to May 2, 2002, at 23 CF care centers in the United States. Of the 251 screened participants with a diagnosis of CF, 185 (74%) were randomized. Eligibility criteria included age 6 years or older, infection with Pseudomonas aeruginosa

JAMA2003

64. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials

Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Lau C Y, Qureshi A K Authors' objectives To evaluate the efficacy and tolerance of azithromycin versus doxycycline for genital chlamydial infection. Searching (...) Studies published in English were retrieved from the following databases: MEDLINE and Pre-MEDLINE (from 1975 to August 2001), HealthSTAR (from 1975 to August 2001), EBM Reviews: Best Evidence (from September 1991 to January/February 2001), EBM Reviews: Cochrane Database of Systematic Reviews (second quarter of 2001), and EBM Reviews: DARE (second quarter of 2001). The medical subject headings 'CT' and 'doxycycline' or 'CT' and 'azithromycin' were used as search terms. Bibliographies of computer

DARE.2002

65. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia

Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest (...) A, Niederman M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative strategies for treating patients with community-acquired pneumonia (CAP) were examined. One strategy was intravenous (IV) to oral azithromycin (AZI

NHS Economic Evaluation Database.2002

66. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial.

Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. 12020525 2002 05 21 2002 06 19 2015 11 19 0140-6736 359 9318 2002 May 11 Lancet (London, England) Lancet Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. 1648-54 The value of azithromycin for treatment of acute bronchitis is unknown, even though this drug is commonly prescribed. We have investigated this question in a randomised, double-blind, controlled trial. Adults diagnosed (...) with acute bronchitis, without evidence of underlying lung disease, were randomly assigned azithromycin (n=112) or vitamin C (n=108) for 5 days (total dose for each 1.5 g). All individuals were also given liquid dextromethorphan and albuterol inhaler with a spacer. The primary outcome was improvement in health-related quality of life at 7 days; an important difference was defined as 0.5 or greater. Analysis was by intention to treat. The study was stopped by the data-monitoring and safety committee when

Lancet2002

67. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. 12383667 2002 10 17 2002 11 19 2015 06 16 0140-6736 360 9338 2002 Sep 28 Lancet (London, England) Lancet Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. 978-84 The macrolide antibiotic azithromycin has anti-inflammatory properties potentially beneficial in cystic fibrosis. Since findings of open pilot studies seemed to show (...) clinical benefit, we undertook a formal trial. 41 children with cystic fibrosis, aged 8-18 years, and with a median forced expiratory volume in 1 s (FEV1) of 61% (range 33-80%) participated in a 15-month randomised double-blind, placebo-controlled crossover trial. They received either azithromycin (bodyweight < or =40 kg: 250 mg daily, >40 kg: 500 mg daily) or placebo for 6 months. After 2 months of washout, the treatments were crossed over. The primary outcome was median relative difference in FEV1

Lancet2002

68. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial.

Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. 12480424 2002 12 13 2002 12 24 2015 06 16 0140-6736 360 9347 2002 Nov 30 Lancet (London, England) Lancet Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. 1722-7 Cholera is a major public-health problem, with children most affected. However, effective single-dose antimicrobial regimens have (...) been identified only for adults. Our aim was to compare the efficacy of azithromycin and erythromycin regimens in the treatment of children. We did a double-blind, randomised study of 128 severely dehydrated children (age 1-15 years) with cholera, treated at one of two treatment centres in Bangladesh in 1999. Children were assigned single-dose azithromycin (20 mg/kg bodyweight, maximum individual dose 1 g; n=65) or 12.5 mg/kg erythromycin (maximum dose 500 mg; n=63) every 6 h for 3 days. Patients

Lancet2002

69. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections

Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower (...) respiratory tract infections Contopoulos-Ioannidis D G, Ioannidis J P, Chew P, Lau J Authors' objectives To carry out a meta-analysis of randomised controlled trials (RCTs) of azithromycin compared with other antibiotics, in the treatment of lower respiratory tract infections including acute bronchitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia. Searching MEDLINE and EMBASE were searched for RCTs published from 1990 to 21 March 2000, using the textword and MeSH 'azithromycin'. The Cochrane Controlled

DARE.2001

70. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections

Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections (...) Ioannidis J P, Contopoulos-Ioannidis D G, Chew P, Lau J Authors' objectives To compare azithromycin in the treatment of upper respiratory tract infections with other antibiotics that are typically administered in longer courses. Searching MEDLINE and EMBASE were searched from 1990 to 21 March 2000 using the textword and MeSH term 'azithromycin'. The Cochrane Controlled Trials Register was also searched. Papers published in English, French, German or Spanish were eligible, as were those published in any

DARE.2001

71. Azithromycin vs. clarithromycin and co-amoxiclav: clinical and economic comparison in the treatment of acute otitis media in children

Azithromycin vs. clarithromycin and co-amoxiclav: clinical and economic comparison in the treatment of acute otitis media in children Azithromycin vs. clarithromycin and co-amoxiclav: clinical and economic comparison in the treatment of acute otitis media in children Azithromycin vs. clarithromycin and co-amoxiclav: clinical and economic comparison in the treatment of acute otitis media in children Kawalski H, Blacha E, Kopacz M, Mos M, Cierpiol-Tracz E, Welniak M, Dudziak B, Bojda S, Kossowska (...) B, Gatniejewska E, Ligacz M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of azithromycin, clarithromycin and co-amoxiclav in the treatment of children with acute otitis media (AOM). Azithromycin was administered

NHS Economic Evaluation Database.2001

72. Atovaquone and azithromycin for the treatment of babesiosis.

Atovaquone and azithromycin for the treatment of babesiosis. 11078770 2000 11 03 2000 11 16 2013 11 21 0028-4793 343 20 2000 Nov 16 The New England journal of medicine N. Engl. J. Med. Atovaquone and azithromycin for the treatment of babesiosis. 1454-8 Babesiosis is a tick-borne, malaria-like illness known to be enzootic in southern New England. A course of clindamycin and quinine is the standard treatment, but this regimen frequently causes adverse reactions and occasionally fails. A promising (...) alternative treatment is atovaquone plus azithromycin. We conducted a prospective, nonblinded, randomized trial of the two regimens in 58 subjects with non-life-threatening babesiosis on Nantucket, on Block Island, and in southern Connecticut. The subjects were assigned to receive either atovaquone (750 mg every 12 hours) and azithromycin (500 mg on day 1 and 250 mg per day thereafter) for seven days (40 subjects) or clindamycin (600 mg every 8 hours) and quinine (650 mg every 8 hours) for seven days (18

NEJM2000

73. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy Sendi P (...) P, Craig B A, Meier G, Pfluger D, Gafni A, Opravil M, Battegay M, Bucher H C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Mycobacterium avium complex (MAC) infection prophylaxis with azithromycin (1,200 mg per week) in HIV

NHS Economic Evaluation Database.1999

74. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group.

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. 10489947 1999 09 28 1999 09 28 2015 06 16 0140-6736 354 9182 1999 Sep 11 Lancet (London, England) Lancet Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. 891-5 Azithromycin in combination with sulphonamides is active against Pneumocystis carinii pneumonia (PCP) in animals. We (...) assessed the clinical efficacy of azithromycin for PCP prophylaxis in human beings. We identified HIV-1-infected patients with PCP during a prospective randomised trial comparing azithromycin, rifabutin, and the two drugs in combination for prevention of disseminated Mycobacterim avium infection. Patients had CD4-cell counts less than 100/microL at entry and received PCP prophylaxis according to the standard practice of their clinician. Analysis was by intention to treat. Patients receiving

Lancet1999

75. Azithromycin in control of trachoma.

Azithromycin in control of trachoma. 10466664 1999 09 07 1999 09 07 2015 06 16 0140-6736 354 9179 1999 Aug 21 Lancet (London, England) Lancet Azithromycin in control of trachoma. 630-5 Trachoma is the leading cause of preventable blindness. Programmes to prevent blindness due to trachoma are based on community-wide treatment with topical tetracycline. We assessed the potential of community-wide azithromycin treatment for trachoma control. Pairs of villages in trachoma endemic areas of Egypt (...) , The Gambia, and Tanzania were matched on trachoma rates in 1-10-year-old children. Villages were randomly assigned community-wide oral azithromycin treatment (three doses with intervals of 1 week) or treatment with 1% topical tetracycline (once daily for 6 weeks). Clinical examinations were done at baseline, 2-4.5 months, and 12-14 months after treatment. Chlamydia trachomatitis was identified by ligase chain reaction (LCR). Analyses were by intention to treat. Univariate comparisons and multivariate

Lancet1999

76. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin

Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin Carbon C, Hotton J M, Pepin L F, Wohlhuter C, Souetre E, Hardens M, Lozet H, Riviera (...) M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Azithromycin vs roxithromycin for the treatment of beta-haemolytic streptococcal pharyngitis. Type of intervention Secondary prevention. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.1996

77. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis

Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Magid D, Douglas J, Schwartz S Record Status (...) . Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Annals of Internal Medicine 1996; 124(4): 389-399 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Analysis of Variance; Azithromycin /administration & Chlamydia Infections /drug therapy /economics; Chlamydia trachomatis; Cost-Benefit Analysis; Decision Trees; Doxycycline /administration & Drug Administration Schedule; Female; Genital Diseases

NHS Economic Evaluation Database.1996

78. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. 8676932 1996 08 09 1996 08 09 2013 11 21 0028-4793 335 6 1996 Aug 08 The New England journal of medicine N. Engl. J. Med. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. 392-8 Azithromycin is active in treating Mycobacterium avium (...) ), azithromycin (1200 mg weekly), or both drugs. They were monitored monthly with blood cultures for M. avium complex. In an intention-to-treat analysis, the incidence of disseminated M. avium complex infection at one year was 15.3 percent with rifabutin, 7.6 percent with azithromycin, and 2.8 percent with both drugs. The risk of the infection in the azithromycin group was half that in the rifabutin group (hazard ratio, 0.53; P = 0.008). The risk was even lower when two-drug prophylaxis was compared

NEJM1996

79. Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study

Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study Sternon J, Leclerq P, Knepper C, Blot K Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Azithromycin or clarithromycin in the treatment of acute purulent tracheobronchitis in adult patients. Clarithromycin (250mg twice daily) was given for 7 to 10 days. Azithromycin was given for 3 days (500mg once daily) or5 days (500mg once daily

NHS Economic Evaluation Database.1995

80. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women

The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women Haddix A C, Hillis S D, Kassler W J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Azithromycin and doxycycline in the treatment of cervical chlamydia infections. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of 10,000 women with clinically suspected genital Chlamydia trachomatis and a cohort of 10,000 women with laboratory confirmed Chlamydia trachomatis. Pregnant women were excluded since

NHS Economic Evaluation Database.1995